952489-53-1

Basic information

• Product Name: C₁₁H₁₀FNO₂
• Synonyms: C₁₁H₁₀FNO₂
• CAS NO: 952489-53-1
• Molecular Weight: 207.204
• Mol File: 952489-53-1.mol

Chemical Properties

• CAS DataBase Reference: C₁₁H₁₀FNO₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₁H₁₀FNO₂(952489-53-1)
• EPA Substance Registry System: C₁₁H₁₀FNO₂(952489-53-1)

Safety Data

• Hazardous Substances Data: 952489-53-1(Hazardous Substances Data)

Upstream product

• 1312412-93-3 1-(4-fluorophenyl)-2,4-dioxopiperidine-3-carboxylic acid ethyl ester 
• 1312412-92-2 N-(2-ethoxycarbonylethyl)-N-(4-fluorophenyl)malonamic acid ethyl ester 
• 887574-32-5 ethyl 3-((4-fluorophenyl)amino)propanoate 

Downstream Products

• 1312412-94-4 3-bromo-1-(4-fluorophenyl)piperidine-2,4-dione 
• 1312415-16-9 5-(4-fluorophenyl)-4-oxo-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid ethyl ester 
• 1312415-17-0 C₁₃H₁₁FN₂O₂S 
• 1312415-19-2 2-chloromethyl-5-(4-fluorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 
• 1312412-62-6 2-benzyloxy-5-(4-fluorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 
• 1312414-26-8 2-(4-fluorophenoxymethyl)-5-(4-fluorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 
• 1312414-29-1 5-(4-fluorophenyl)-2-phenoxymethyl-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 
• 1312414-51-9 2-(2-fluorophenoxymethyl)-5-(4-fluorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 
• 1312414-45-1 2-(3-fluorophenoxymethyl)-5-(4-fluorophenyl)-6,7-dihydro-5H-thiazolo[5,4-c]pyridin-4-one 

Relevant articles and documents

Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor

Starting from a singleton chromanone high throughput screening (HTS) hit, we describe a focused medicinal chemistry optimization effort leading to the identification of a novel series of phenoxymethyl-dihydrothiazolopyridone derivatives as selective positive allosteric modulators (PAMs) of the metabotropic glutamate 5 (mGlu5) receptor. These dihydrothiazolopyridones potentiate receptor responses in recombinant systems. In vitro and in vivo drug metabolism and pharmacokinetic (DMPK) evaluation allowed us to select compound 16a for its assessment in a preclinical animal screen of possible antipsychotic activity. 16a was able to reverse amphetamine-induced hyperlocomotion in rats in a dose-dependent manner without showing any significant motor impairment or overt neurological side effects at comparable doses. Evolution of our medicinal chemistry program, structure activity, and properties relationships (SAR and SPR) analysis as well as a detailed profile for optimized mGlu5 receptor PAM 16a are described.

BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.

BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

The present invention relates to novel bicyclic thiazoles of formula (I) which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ("mGluR5") and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.

BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

The present invention relates to novel bicyclic thiazoles of formula (I) which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ("mGluR5") and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.